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Abstract 
Background: The use of checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) has revolutionised the 
treatment of metastatic melanoma. However still more than the half the patients do not respond to single-agent 
immunotherapy. This has led to the development of combining these agents in an attempt to enhance the anti-can-
cer activity. More than 300 different studies with 15 different drug doses are currently ongoing. Combining different 
checkpoint inhibitors (CPIs) does indeed lead to an increase in response rate, but this is associated with significant 
toxicity. IMM-101 is a heat killed Mycobacterium preparation which induces marked immune modulation and little 
systemic toxicity. It has been reported as having activity in melanoma as single agent and in pancreatic cancer in 
combination with gemcitabine, the latter in a randomised study.
Methods: Here we report the effect of adding CPIs to 3 patients who had previously been on IMM-101, either as a 
trial or a named patient programme and a patient who received the IMM-101 together with nivolumab.
Results: All 4 patients had rapid and very good responses, three of them maintained over 18 months with no signifi-
cant additional toxicity.
Conclusions: The rapid and complete clinical responses seen in these patients may suggest that IMM-101 is activat-
ing a complementary pathway which is synergistic with CPI treatment.
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Background
Immune checkpoint blockades or checkpoint inhibi-
tors (CPIs) have emerged as a major breakthrough 
for patients with metastatic melanoma and more 
recently they have been licensed in other tumour 
types. Ipilimumab is an anti-CTLA-4 antibody which 
showed to significantly improve long term survival 
of patients with metastatic melanoma being up to 
20% of the treated patients alive at 5  years in spite of 
a low response rate (overall response rate [ORR] is 
around 10% with a complete response [CR] rate of 
less than 3%) [1]. Anti-PD1 antibodies (pembroli-
zumab and nivolumab) have shown higher response 
rates (ORR around 40%) and long duration of response 
with a more favourable toxicity profile in comparison 
to ipilimumab [2–4]. The combination of nivolumab 
and ipilimumab has shown even higher response 
rates (58% ORR with 19% CR) similar to the ones 
seen with BRAF + MEK inhibitors, but this came at 
a price of greater toxicity (55% of the patients on the 
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combination regiment experience a major toxicity 
which usually requires hospitalization and treatment 
discontinuation) [4]. The full details of these piv-
otal trials have been reviewed elsewhere [5]. In spite 
of these major advances about the half the patients 
do not respond to immunotherapy. This has resulted 
in attempts to maximise the clinical benefit whilst 
reducing overall toxicity. In addition, there has been 
a major effort to identify those patients more likely 
to respond to immunotherapy and to exclude those 
unlikely to benefit. Lastly, efforts are made to convert 
non-responders into responders. Unfortunately most 
attempts to improve the clinical outcome involve com-
bination with other agents and usually result in signifi-
cant additional toxicity.
IMM-101 is a suspension of heat-killed whole cell 
Mycobacterium obuense (M. obuense) sourced from 
the National Collection of Type Cultures (NCTC) with 
reference NCTC 13365 in borate-buffered saline, pro-
duced in accordance with good manufacturing prac-
tice (GMP) for intradermal administration to humans. 
It is usually given as a single 0.1 mL intradermal injec-
tion of IMM-101 (10  mg/mL) into the skin overlying 
the deltoid muscle with an induction phase of 9 weeks 
initially and a maintenance phase thereafter. It is a 
non-specific immune modulator and has not shown 
significant systemic toxicity. It has demonstrated 
to induce clinical responses in stage IV melanoma 
patients (especially cutaneous and lung metastases) 
(IMM-101-001 study) as well as resulting in prolonged 
5  years survival (IMM-101-008 study) in this small 
cohort [6, 7]. In combination with gemcitabine it has 
shown to significantly improve the survival outcomes 
of patients with metastatic pancreatic cancer, as com-
pared to gemcitabine alone [8]. IMM-101 has been well 
tolerated overall in clinical studies to date, including 
over extended dosing periods for some patients. The 
only treatment-related adverse events to have occurred 
in more than 10% of patients when analysed across all 
clinical studies to date are mild pyrexia (10.5%) and 
injection site reactions (12.4%).
Methods
Here we report on three cases who have received treat-
ment with IMM-101 on the IMM-101-001 study prior 
to a checkpoint blockade and on a case who received 
nivolumab and IMM-101 concomitantly. All experienced 
very good response to treatment, one of which com-
menced within 4 days of adding pembrolizumab.
Results
A total of 11 patients with metastatic melanoma have 
been treated with IMM-101 and a checkpoint inhibi-
tor either sequentially (n = 9) or concomitantly (n = 2). 
Five patients experienced a disease progression, whereas 
the remaining patients had stability of disease at first re-
assessment on treatment (n = 1) or an objective response 
(n = 5). Four patients had an exceptionally good and 
rapid response and their characteristics are summarized 
in Table 1.
Patient 1
A 46 year old male who presented in 2006 with a 3.7 mm 
BT (Breslow thickness), BRAF wild-type melanoma on 
his left forearm. He had 1 positive lymph node at SNB 
(Sentinel Node Biopsy) with no further nodal involve-
ment at left axillary dissection. He had over the years 
multiple subcutaneous loco-regional recurrences treated 
with surgical resections initially and then with topical 
imiquimod and intra-tumour IL-2, as per Green et  al. 
[9]. Further recurrences led to him being enrolled on 
the IMM-101-001 study, which resulted in a reduction 
in the rate of new disease. Following the development 
of lung metastases he stopped IMM-101 and received 
6  weeks thereafter ipilimumab on a clinical trial. On 
ipilimumab he experienced a rapid very good response 
(partial response [PR] > 50% as per RECIST 1.1 criteria) 
with most of the lesions resolving and a couple of visceral 
lesions remaining stable now over 5 years (Fig. 1).
Patient 2
A 50 year-old female who presented in 2011 with an axil-
lary mass, which on removal was shown to be a BRAF 
Table 1 Patients’ characteristics at time of administration of IMM-101
Patient 1 Patient 2 Patient 3 Patient 4
M1 stage AJCC v.8 M1a (0) M1c (1) M1c (0) M1b (0)
Baseline LDH Normal Abnormal Abnormal Normal
BRAF status Wild-type Wild-type Wild-type Wild-type
Number of metastases 6 > 10 > 10 5
Sites of metastases Subcutaneous Lung, peritoneum, stomach, 
nodes
Lung, subcutaneous, nodes, 
adrenal
Lung, subcutaneous
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wild-type metastatic melanoma. No primary tumour was 
identified. She developed mediastinal, lung, gastric and 
peritoneal deposits within a couple of months from ini-
tial diagnosis. She had a partial gastrectomy to remove 
the cancer which was bleeding, and cyberknife treatment 
for the metastatic lung lesion. She also received systemic 
treatment with dacarbazine followed by IMM-101 on the 
IMM-101-001 study, which resulted in a minor response. 
She remained however stable for about a year until 2013 
when she presented with a small bowel obstruction from 
new disease. She stopped IMM-101 and started ipili-
mumab and experienced a rapid complete response as 
per RECIST 1.1 criteria, which continued for 2  years 
until she had a further recurrence following trauma and 
stress in 2015. She is still disease free at the moment after 
further surgery.
Patient 3
A 79 year-old male presented in 2014 with a melanoma 
on his left cheek (BT 2.4 mm, not ulcerated, BRAF wild-
type) with a positive SNB leading to left neck dissection 
at time of diagnosis (no further positive nodes). Within 
months he developed paracardiac nodes, adrenal, lung 
and multiple large subcutaneous metastatic deposits. 
In view of his age and performance status he was com-
menced on IMM-101 on a named-patient program with 
initial stabilisation of disease. Upon progression of the 
subcutaneous disease he stopped IMM-101 and started 
with pembrolizumab, which showed a very rapid ben-
efit as the subcutaneous lesions started to shrink within 
4 days of the first infusion (Fig. 2). All visceral disease had 
also responded as seen on a restaging CT scan performed 
6  weeks later with a PR > 50% as per RECIST1.1 crite-
ria initially followed by a CR a few months afterwards 
(Fig.  3) upon continuation of pembrolizumab which 
lasted for 18 months and is still ongoing.
Patient 4
A 63-year old male who presented in July 2016 with a 
4.2  mm BT ulcerated BRAF wild-type nodular mela-
noma on his right upper back. He underwent wide local 
excision and SNB of his right axilla in September 2016 
(N + 3/5) followed by completion of the lymphadenec-
tomy in October 2016 (N + total 3/15). In May 2017 he 
developed subcutaneous metastases on the right lower 
leg, right forearm and anterior scalp. At the same time 
a re-staging CT scan showed new pulmonary disease (at 
least 3 metastatic nodules, the bigger measuring 1.6 cm 
in the larger diameter). He was then enrolled in the IMM-
101-011 study aiming to evaluate the safety and efficacy 
of IMM-101 in combination with standard of care in 
patients with metastatic cancer. On the 1st of June 2016 
he started treatment with nivolumab in combination 
with IMM-101. The combination treatment has been well 
tolerated with no major toxicities apart from transient 
hyperthyroidism. A minor response to treatment (SD as 
per RECIST 1.1 criteria) was observed at first re-assess-
ment in August 2016 with a complete response achieved 
in December 2017. IMM-101 has been administered 
regularly every 4  weeks on the named-patient program 
after trial closure till December 2017 when he developed 
a grade 3 skin reaction at the site of the latest injection 
of IMM-101. Since then the treatment with IMM-101 has 
been postponed and rescheduled every 3 months.
Fig. 1 Significant response seen in a 46 year-old male with stage IV melanoma treated with ipilimumab after IMM-101 with most of the lesions 
resolving and a couple remaining stable over a long period of time
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Discussion
IMM-101 was developed following considerable clini-
cal experience with a similar agent, Mycobacterium vac-
cae, which was reported as inducing clinical responses 
in low volume metastatic melanoma, as well as enhanc-
ing the effect of other therapies [10, 11]. This led to 
many patients with advanced disease becoming man-
ageable with other treatments, including surgery, result-
ing in a 5 years OS of over 20% in a phase II study [11]. 
Heat-killed M. vaccae was produced by SR Pharma and 
called SRL-172, but was eventually dropped in favour of 
mRNA-silencing technology when the company changed 
its name to Silence Therapeutics. IMM-101, based on M. 
obuense was selected by Immodulon Therapeutics as a 
similar but more suitable agent for clinical development. 
An early phase II with this agent showed a similar pattern 
of clinical responses, as seen with SRL-172, and increased 
OS (30% at 5 years) [6, 7].
IMM-101 generates an aspecific immune response 
and its full mechanism of action is still under inves-
tigation. Exposure of IMM-101 has shown to prime 
in  vitro generated murine dendritic cells and human 
monocyte-derived DC in a dose dependent manner 
that functionally affects DC by enhancing their ability 
to process and present antigen [12, 13]. Furthermore 
it has been observed that IMM-101 activated DCs are 
able to promote  CD8+ and  CD4+ (Th-1) T cell secretion 
of IFN-γ following re-stimulation of draining lymph 
node cell preparations, 7 days after subcutaneous adop-
tive transfer of IMM-101 primed DC into naïve recipi-
ent mice [12]. In this experiment, it was not only shown 
that IMM-101 stimulated DCs lead to a large increase 
in the number of IFN-γ producing T cells, but also to 
a similar large increase of IFN-γ producing natural 
killer (NK) and γδ-T cells in the draining lymph node. 
In another experiment, Fowler et al. showed that IMM-
101 activates γδ-T cells via cytokines produced by type 
1 DCs [14]. These findings may suggest that IMM-101 
through the activation of DCs is able to stimulate the 
formation of activated cytotoxic T cells (CTLs), NK and 
γδ-T cells, which are all crucial for killing cancer cells.
In a murine model of lung metastasis, IMM-101 
showed a significant effect on the metastatic capacity 
Fig. 2 Complete reponse observed in a 79 year-old male with stage IV melanoma treated with IMM-101 followed by pembrolizumab 
(subcutaneous disease). The subcutaneous lesions started to shrink within 4 days of the first infusion of pembrolizumab
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of CT26 tumour cell injected intravenously by reducing 
the metastatic burden [15].
In a murine model with the breast cancer cell line 
EMT-6, IMM-101 showed to increase the response to 
anti-PD1 antibodies, resulting in a significant (i) reduc-
tion of tumour volume, (ii) increase of the intra-tumour 
 CD8+ T cells/Treg ratio and (iii) increase of the IFN-γ/
IL-10 ratio in spleen cells compared to anti-PD1 alone 
[16]. In similar mice experiments using murine pancreas 
and melanoma cancer cell lines it was also found that the 
combination treatment of IMM-101 with a CPI (both 
anti-PDL-1 and anti-CTLA-4 were tested) had stronger 
anti-tumour effects than the CPI alone (unpublished 
results and [17]).
In the above mentioned preclinical studies IMM-101 
has shown to stimulate an immune response suppressed 
by the underlying tumour, which may enhance responses 
to other modalities of treatment. Altogether 11 patients 
with metastatic melanoma have been treated with IMM-
101 and CPIs either sequentially or concomitantly. 
Despite the majority of these patients were previously 
pre-treated, about the half of them experienced some 
kind of benefit. Four of them had an exceptionally good 
and rapid response and have been presented here. The 
CR rate with ipilimumab in melanoma is less than 3%. 
We reported 2 cases that had both received prior IMM-
101 treatment and experienced a very good response 
with ipilimumab; one CR which lasted for a couple of 
years until unexpected trauma and the other with no new 
disease for 5 years. Although the CR for PD-1 inhibitors 
is higher, complete responses may take months before 
they become manifest. Here we presented a case of wide-
spread stage IV M1c disease that had, following prior 
IMM-101 treatment, an objective response observed 
4 days after the first infusion with the anti-PD1 antibody 
pembrolizumab and another case of a rapid complete 
response to treatment when IMM-101 was given in com-
bination with the anti-PD1 antibody nivolumab.
Based on our experience with IMM-101 (either as part 
of a clinical trial or a named-patient program with several 
different cancers) and with CPIs in melanoma, we think 
that the use of IMM-101 in these 4 patients may have 
enhanced the effects of the CPIs resulting into the very 
good and rapid responses seen in these patients. IMM-
101 may have activated in these patients a complemen-
tary pathway which is synergistic with CPI treatment.
Fig. 3 Complete reponse observed in a 79 year-old male with stage IV melanoma treated with IMM-101 followed by pembrolizumab (lung disease)
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Using murine melanoma models, Salmon et  al. [18] 
have shown that  CD103+ dendritic cells (so-called cDC1 
cells, a special subclass of DCs that elicit type I immune 
responses which are required for effective anti-tumour 
responses) were the only antigen presenting cells (APCs) 
that, following proper activation by danger signals (such 
as danger-associated molecular patterns (DAMPs) from 
dying tumour cells and pathogen-associated molecular 
patterns (PAMPs) from microbes [19, 20], were able of 
transporting tumour antigens to the lymph nodes and 
capable of priming there  CD8+ T-cells and transform-
ing them into CTLs. In these murine melanoma models, 
 CD103+ DCs were required to promote the anti-tumour 
effects of administered anti PD-L1, which only had par-
tial activity when used alone. Salmon et al. showed that 
a therapy of Fit3L (growth factor for DCs) combined 
with poly1:C (a PAMP that activates DCs) can enhance 
the anti-tumour responses of CPIs in murine models 
by inducing  CD103+ DC maturation, proliferation and 
activation. cDC1 have the unique ability of cross pres-
entation of (tumour) antigen epitopes embedded in class 
I major histocompatibility complex molecules [HLA 
I (mice) and MHC I (human)], which is a prerequisite 
for the recognition of these (tumour) antigens by  CD8+ 
T-cells and their subsequent priming, maturation, activa-
tion and proliferation.
IMM-101 has been shown to activate naïve mouse and 
human DCs into DCs that are capable to effectively pre-
sent antigens and to elicit the required type I immune 
response [12, 13, 16, 21] that Salmon et  al. found to be 
required for effective CPI responses. Humans do not 
have  CD103+ DCs but they do have similar  (CD141+) 
cDC1-like cells capable of priming  CD8+ T-cells when 
activated [22]. In humans, IMM-101 is given intrader-
mally and it is assumed that it activates intradermal DCs 
(and possibly also Langerhans cells) with its PAMPs. 
Following activation, these DCs migrate to the lymph 
nodes, an activity that was readily demonstrated by PET 
scan following IMM-101 administration (unpublished 
results). As mentioned above, in mouse models, IMM-
101 induces a powerful Th-1 and CTL cytokine response, 
which attenuates unwanted Th-2 responses and high 
levels of IFN-γ can be found in lymph nodes contain-
ing IMM-101 activated DCs. This IFN-γ was found to 
be produced not only by increased numbers of Th-1 and 
CTLs, but also by similar increased numbers of activated 
NK and γδ-T cells, which are all cells that, after traveling 
to the tumour, are together required for a highly effective 
anti-tumour response. It is this systemic type I immune 
modulating activity that suggests that the human equiva-
lent of  CD103+ DCs may be activated by intra-dermally 
injected IMM-101, leading to the enhancement of CPI 
responses. Clearly further work to confirm the cDC1 
activation as the dominant explanation of the observed 
synergy between IMM-101 and CPIs are needed.
Conclusion
Our positive experiences with these 4 patients and the 
absence of any severe systemic toxicity clearly warrants 
in our view a pilot clinical trial to assess the safety and 
the efficacy of IMM-101 in combination with nivolumab 
in metastatic melanoma patients. Such a trial (IMM-101-
015) is expected to start mid-2018.
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